‘Testing bottleneck’ for monkeypox in the U.S.; the graveyard of health tech pilots

The CDC's two-step system is seen as not quick enough to help clinicians who should be actively looking for monkeypox infections. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      'Testing bottleneck' for monkeypox puts hope of containment at risk, experts warn By Helen Branswell and Andrew Joseph Pablo Blazquez Dominguez/Getty Images The CDC's two-step system is seen as not quick enough to help clinicians who should be actively looking for monkeypox infections. Read More STAT+: The graveyard of health tech pilots: why some experiments flourish and others fizzle By Mohana Ravindranath Hyacinth Empinado/STAT Failed pilots can teach hospitals and health tech companies about what technologies are actually useful, and how to roll them out well. Read More STAT+: A dose of transparency by Cel-Sci does nothing to burnish its failed cancer immunotherapy By Adam Feuerstein The outcome of the Cel-Sci Phase 3 study of the immunotherapy Multikine in patients with head and neck cancer is clear. Read More Sponsor content by Astellas Biomarkers are at the forefront of gastric cancer research — learn about their evolving role In the U.S., gastric cancer is often diagnosed in advanced stages when it is aggressive and as such, expected outcomes are poor. An essential part of understanding an individual's cancer at this stage is taking a closer look at their tumor to better understand its unique profile and identify specific biomarkers. Established and emerging biomarkers can expand views of previously unidentified patient subsets and may inform clinical decisions. Visit GastricCancerBiomarkers.com to learn more about the evolving landscape of biomarker research. STAT+: Study suggests a new harm from hospital mergers: less price transparency By Tara Bannow Adobe A JAMA study highlights a new downside to hospital mergers: lower adherence to federal laws about price transparency. Read More STAT+: 'All about strengthening health systems': New coalition pushes to license cancer drugs to low-income countries By Ed Silverman Melissa Rendler-Garcia of UICC spoke with STAT about a new effort to license cancer drugs in low-income countries. Read More STAT+: Watch: An interview with the FDA's top cancer regulator By Matthew Herper FDA Rich Pazdur, the director of the FDA Oncology Center of Excellence, addressed rapid approvals, diversity in clinical trials, and more. Read More Opinion: It's time to move past Aduhelm and focus on a broader Alzheimer's drug pipeline By Howard M. Fillit Adobe Alzheimer's is not a one-cause-explains-all disease. That's why researchers must take a broader and more diverse approach finding new therapies. Read More STAT+: Former Lilly manager files whistleblower lawsuit over manufacturing failures at production plant By Ed Silverman A former Eli Lilly employee is suing the drugmaker. She says she lost her job for alerting management to manufacturing problems. Read More Tuesday, June 7, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser